Last reviewed · How we verify
Travoprost/timolol therapy
Travoprost/timolol is a fixed-dose combination that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor (travoprost) and decreasing aqueous humor production (timolol).
Travoprost/timolol is a fixed-dose combination that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor (travoprost) and decreasing aqueous humor production (timolol). Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Travoprost/timolol therapy |
|---|---|
| Also known as | DuoTrav BAK Free |
| Sponsor | Aristotle University Of Thessaloniki |
| Drug class | Prostaglandin analog/beta-blocker combination |
| Target | Prostaglandin F receptor (FP receptor) and beta-adrenergic receptors (beta-1 and beta-2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Travoprost is a prostaglandin F analog that binds to prostaglandin F receptors and enhances drainage of aqueous humor through the uveoscleral pathway. Timolol is a non-selective beta-adrenergic antagonist that decreases aqueous humor production by inhibiting beta-2 adrenergic receptors on the ciliary body. Together, these complementary mechanisms provide additive intraocular pressure reduction.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation/discomfort
- Iris pigmentation increase
- Eyelash growth
- Bradycardia
- Bronchospasm
Key clinical trials
- Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues
- Stop Retinal Ganglion Cell Dysfunction Study (PHASE3)
- Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
- 24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG (PHASE4)
- 24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol (PHASE4)
- Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma (PHASE4)
- Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® (PHASE4)
- The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Travoprost/timolol therapy CI brief — competitive landscape report
- Travoprost/timolol therapy updates RSS · CI watch RSS
- Aristotle University Of Thessaloniki portfolio CI